JRHIF yields 4.84% · PFE yields 6.13%● Live data
📍 JRHIF pulled ahead of the other in Year 1
Combined, JRHIF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JRHIF + PFE for your $10,000?
Daiwa Securities Living Investment Corporation (hereinafter referred to as "the Investment Corporation") is listed on the Tokyo Stock Exchange in June 2006 (stock code: 8986) and is located in the metropolitan area and major cities throughout Japan (Sapporo City, Sendai City) It is a rental apartment specialized REIT (REIT) that invests in rental apartments in Nagoya City, Osaka City, Fukuoka City, etc. After the acquisition of Prospect Reit Investment Corporation in July 2010, the Investment Corporation will actively replace properties (acquisition of new properties) with the management ability of the asset management company Daiwa Real Estate Asset Management Co., Ltd. And the sale of existing properties), drastic operation reinforcement (achievement of high occupancy rate), various cost reductions, etc., and we have achieved improvement in distribution. In December 2015, Daiwa Securities Group Inc. (hereinafter referred to as "Daiwa Securities Group Inc.") will acquire additional shares of the asset management company, and the Investment Corporation will bring Daiwa Securities Group Inc. as a new sponsor have become. The Investment Corporation will use its support based on the sponsor-support agreement concluded between the asset management company and the Daiwa Securities Group headquarters to aim for sustainable and stable growth. The Investment Corporation will continue to aim to maximize the profits of its investors. We would like to ask all investors for their continued support and rewards.
Full JRHIF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.